Linatab
Generic Name
Linagliptin
Manufacturer
Incepta Pharmaceuticals Ltd.
Country
Bangladesh
Loading images...
Price Details
Current market pricing information
| Variant | Unit Price | Strip Price |
|---|---|---|
| linatab 5 mg tablet | ৳ 20.00 | ৳ 200.00 |
Description
Overview of the medicine
Linatab (Linagliptin) is an oral antidiabetic drug used to improve blood sugar control in adults with type 2 diabetes mellitus. It is used alone or in combination with other diabetes medications.
Uses & Indications
Dosage
Adults
The recommended dose of Linagliptin is 5 mg orally once daily.
Elderly
No dose adjustment is required for elderly patients.
Renal_impairment
No dose adjustment is required for patients with renal impairment.
How to Take
Linatab should be taken orally once daily, with or without food. Swallow the tablet whole with water.
Mechanism of Action
Linagliptin works by inhibiting the enzyme Dipeptidyl Peptidase-4 (DPP-4). By blocking DPP-4, linagliptin increases the levels of incretin hormones (GLP-1 and GIP), which are naturally released after a meal. These hormones increase insulin synthesis and release from the pancreas in a glucose-dependent manner and decrease glucagon secretion, leading to lower blood glucose levels.
Pharmacokinetics
Onset
Glucose-lowering effects observed within 24 hours.
Excretion
Primarily eliminated via the enterohepatic system, with approximately 80% excreted unchanged in feces and 5% in urine. Renal excretion is a minor pathway.
Half life
The terminal half-life is approximately 131 hours, but the effective half-life for DPP-4 inhibition is about 12-18 hours.
Absorption
Rapidly absorbed after oral administration, with peak plasma concentrations occurring approximately 1.5 hours post-dose. Absolute bioavailability is about 30%.
Metabolism
Limited metabolism; only a small fraction is metabolized by CYP3A4. The main metabolic pathway involves cleavage of the piperidine ring.
Side Effects
Contraindications
- Hypersensitivity to linagliptin or any component of the formulation.
- History of serious hypersensitivity reaction to linagliptin (e.g., anaphylaxis, angioedema, exfoliative skin conditions).
Drug Interactions
Rifampicin
Co-administration with rifampicin (a P-gp/CYP3A4 inducer) significantly decreased linagliptin exposure, thus the efficacy of linagliptin may be reduced when administered in combination with a strong P-gp/CYP3A4 inducer.
Metformin, Sulfonylureas, Digoxin, Warfarin, Simvastatin
No clinically significant pharmacokinetic interactions.
Storage
Store below 30°C in a dry place, away from light and moisture. Keep out of reach of children.
Overdose
In the event of an overdose, contact a healthcare professional or poison control center immediately. Symptomatic treatment and supportive measures should be initiated as appropriate.
Pregnancy & Lactation
Pregnancy Category B. Studies in animals have shown no evidence of harm to the fetus, but there are no adequate and well-controlled studies in pregnant women. Use during pregnancy only if clearly needed. It is not known whether linagliptin is excreted in human milk. Exercise caution when administered to a nursing woman.
Frequently Asked Questions
Common questions about this medicine
Pack Sizes
Shelf Life
Typically 24-36 months from the date of manufacture.
Availability
Available in pharmacies across Bangladesh
Approval Status
Approved by DGDA (Bangladesh) & FDA (USA)
Patent Status
Generically available in Bangladesh (Originally patented by Boehringer Ingelheim)
Clinical Trials
Extensive clinical trials have demonstrated the efficacy and safety of linagliptin in various patient populations with type 2 diabetes, both as monotherapy and in combination with other antidiabetic agents.
Lab Monitoring
- Glycated hemoglobin (HbA1c) levels should be monitored regularly to assess glycemic control.
- Monitor renal function periodically (although no dose adjustment is needed for impairment).
- Liver function tests are generally not required but may be considered in patients with pre-existing hepatic issues.
Doctor Notes
- Emphasize the importance of lifestyle modifications (diet, exercise) alongside Linatab for optimal glycemic control.
- Consider combination therapy if monotherapy with Linatab is insufficient.
- Advise patients to report any symptoms of pancreatitis (e.g., severe abdominal pain, nausea, vomiting) immediately.
Patient Guidelines
- Take Linatab exactly as prescribed by your doctor.
- Do not stop taking Linatab without consulting your doctor.
- Follow diet and exercise recommendations provided by your healthcare provider.
- Monitor your blood sugar levels regularly as advised.
Missed Dose Advice
If a dose is missed, take it as soon as you remember. If it is almost time for your next dose, skip the missed dose and continue with your regular dosing schedule. Do not take a double dose to make up for a missed one.
Driving Precautions
Linatab is unlikely to affect the ability to drive or operate machinery. However, if used in combination with a sulfonylurea or insulin, there is a risk of hypoglycemia, which could impair driving ability. Patients should be advised on the signs and symptoms of hypoglycemia and how to manage them.
Lifestyle Advice
- Maintain a balanced diet low in sugar and refined carbohydrates.
- Engage in regular physical activity.
- Manage weight to improve glycemic control.
- Limit alcohol consumption.
Alternative Medicines in Bangladesh
Similar medicines available in the market
Global Brand Names
International brand names for this medicine. Click a brand to search for detailed information.